{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:41:23Z","timestamp":1793320883045,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40121-024-01067-1","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T14:48:11Z","timestamp":1731077291000},"page":"2597-2615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Na\u00efve Adults Aged\u2009\u2265\u200965 Years in the United States"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4997-3121","authenticated-orcid":false,"given":"Zinan","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Owusu-Edusei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elamin","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"1067_CR1","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal vaccine for adults aged \u226519 years: recommendations of the advisory committee on immunization practices, United States, 2023. MMWR Recomm Rep. 2023;72(3):1\u201339.","DOI":"10.15585\/mmwr.rr7203a1"},{"key":"1067_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.824788","volume":"12","author":"AD Gingerich","year":"2022","unstructured":"Gingerich AD, Mousa JJ. Diverse mechanisms of protective anti-pneumococcal antibodies. Front Cell Infect Microbiol. 2022;12: 824788.","journal-title":"Front Cell Infect Microbiol"},{"key":"1067_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00540-21","author":"F Ganaie","year":"2021","unstructured":"Ganaie F, Maruhn K, Li CX, et al. Structural, genetic, and serological elucidation of serogroup 24 serotypes: discovery of a new serotype, 24C, with a variable capsule structure. J Clin Microbiol. 2021. https:\/\/doi.org\/10.1128\/JCM.00540-21.","journal-title":"J Clin Microbiol"},{"key":"1067_CR4","doi-asserted-by":"publisher","unstructured":"Ganaie F, Saad JS, McGee L, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. mBio. 2020. https:\/\/doi.org\/10.1128\/mBio.00937-20.","DOI":"10.1128\/mBio.00937-20"},{"key":"1067_CR5","doi-asserted-by":"crossref","unstructured":"Werren JP, Troxler LJ, Oyewole OR, et al. Carbon source-dependent changes of the structure of Streptococcus pneumoniae capsular polysaccharide with serotype 6F. Int J Mol Sci. 2021;22(9):4580.","DOI":"10.3390\/ijms22094580"},{"key":"1067_CR6","doi-asserted-by":"crossref","unstructured":"Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355\u201367.","DOI":"10.1038\/s41579-018-0001-8"},{"key":"1067_CR7","unstructured":"Global Burden of Disease 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191\u2013210."},{"key":"1067_CR8","unstructured":"Gierke R, McGee L, Beall B, Pilishivili T. Chapter 11: Pneumococcal. In: Centers for Disease Control and Prevention, editor. Manual for the surveillance of vaccine-preventable diseases. 2020. Available from: https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt11-pneumo.html. Accessed May 2023."},{"issue":"36","key":"1067_CR9","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1016\/j.vaccine.2009.05.061","volume":"27","author":"I Ogilvie","year":"2009","unstructured":"Ogilvie I, Khoury AE, Cui Y, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27(36):4891\u2013904.","journal-title":"Vaccine"},{"key":"1067_CR10","doi-asserted-by":"crossref","unstructured":"van de Beek D, de Gans J, Tunkel AR, Wijdicks EFM. Current concepts: community-acquired bacterial meningitis in adults. N Engl J Med. 2006;354(1):44\u201353.","DOI":"10.1056\/NEJMra052116"},{"issue":"4","key":"1067_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060273","volume":"8","author":"MA Said","year":"2013","unstructured":"Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE. 2013;8(4): e60273.","journal-title":"PLoS ONE"},{"issue":"11","key":"1067_CR12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/cid\/ciy800","volume":"68","author":"SI Pelton","year":"2019","unstructured":"Pelton SI, Bornheimer R, Doroff R, et al. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019;68(11):1831\u20138.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1067_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","volume":"70","author":"A Torres","year":"2015","unstructured":"Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984\u20139.","journal-title":"Thorax"},{"key":"1067_CR14","unstructured":"Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(9):1\u201335."},{"key":"1067_CR15","unstructured":"Centers for Disease Control and Prevention. ABCs Bact Facts Interactive Data Dashboard. Atlanta, GA: Centers for Disease Control and Prevention; 2024."},{"key":"1067_CR16","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Stoecker C, Xing W, Cho BH, Pilishvili T. Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions. Hum Vaccin Immunother. 2021;1\u20139.","DOI":"10.1093\/ofid\/ofaa439.065"},{"key":"1067_CR17","unstructured":"Kobayashi M. Preliminary work group interpretations of EtR and next steps. Presentation to the ACIP, February 29, 2024. Atlanta, GA: Centers for Disease Control and Prevention; 2024."},{"key":"1067_CR18","doi-asserted-by":"crossref","unstructured":"Arnold FW, Reyes Vega AM, Salunkhe V, et al. Older adults hospitalized for pneumonia in the United States: incidence, epidemiology, and outcomes. J Am Geriatr Soc. 2020;68(5):1007\u201314.","DOI":"10.1111\/jgs.16327"},{"key":"1067_CR19","unstructured":"Merck & Co. Safety and immunogenicity of V116 in pneumococcal vaccine-na\u00efve adults (V116-003, STRIDE-3). Rahway, NJ: Merck & Co.; 2022. https:\/\/classic.clinicaltrials.gov\/show\/NCT05425732. Accessed 20 June 2024."},{"key":"1067_CR20","unstructured":"Food and Drug Administration. CAPVAXIVE\u2122 (pneumococcal 21-valent conjugate vaccine): United States prescription information. June 17, 2024. Available from: https:\/\/www.fda.gov\/media\/179426\/download. Accessed 20 June 2024."},{"key":"1067_CR21","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793\u2013798.","DOI":"10.15585\/mmwr.mm7336a3"},{"key":"1067_CR22","unstructured":"Gierke R. Current epidemiology of pneumococcal disease among adults, United States. Presentation to the ACIP, February 29, 2024. Atlanta, GA: Centers for Disease Control and Prevention; 2024."},{"key":"1067_CR23","unstructured":"Centers for Disease Control and Prevention. 1998\u20132021 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance. Atlanta, GA: Active Bacterial Core Surveillance; 2023."},{"key":"1067_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-00988-1","author":"Z Yi","year":"2024","unstructured":"Yi Z, Johnson K, Owusu-Edusei K. Lifetime health and economic burden of invasive pneumococcal diseases attributable to V116 serotypes among adults in the United States. Infect Dis Ther. 2024. https:\/\/doi.org\/10.1007\/s40121-024-00988-1.","journal-title":"Infect Dis Ther."},{"key":"1067_CR25","unstructured":"Merck & Co. U.S. FDA approves CAPVAXIVE\u2122 (pneumococcal 21-valent conjugate vaccine) for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Rahway, NJ: Merck & Co.; 2024."},{"key":"1067_CR26","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among US adults: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022. MMWR Morbi Mortal Wkly Rep. 2022;71(4):109\u201317.","DOI":"10.15585\/mmwr.mm7104a1"},{"key":"1067_CR27","unstructured":"Loehr J. Pneumococcal vaccines. Presentation to the ACIP, February 29, 2024. Atlanta, GA: Centers for Disease Control and Prevention; 2024."},{"issue":"8","key":"1067_CR28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s11606-016-3651-0","volume":"31","author":"C Stoecker","year":"2016","unstructured":"Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31(8):901\u20138.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"1067_CR29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.vaccine.2018.01.052","volume":"36","author":"C Chen","year":"2018","unstructured":"Chen C, Wood J, Beutels P, et al. The role of timeliness in the cost-effectiveness of older adult vaccination: a case study of pneumococcal conjugate vaccine in Australia. Vaccine. 2018;36(10):1265\u201371.","journal-title":"Vaccine"},{"key":"1067_CR30","unstructured":"Bureau of Labor Statistics. CPI for All Urban Consumers (CPI-U): medical care in U.S. city average, all urban consumers, not seasonally adjusted. Washington, DC: Bureau of Labor Statistics; 2023."},{"key":"1067_CR31","doi-asserted-by":"crossref","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(15):1253\u20138.","DOI":"10.1001\/jama.276.15.1253"},{"key":"1067_CR32","unstructured":"Hun M-C, Srivastav A, Lu P-J, et al. Vaccination coverage among adults in the United States. National Health Interview Survey, 2021. 2022. Available from: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/vaccination-coverage-adults-2021.html. Accessed 20 June 2024."},{"key":"1067_CR33","unstructured":"Stoecker C. Economic assessment of PCV20 for adults vaccinated with PCV13. Presented at ACIP, October 19, 2022. Atlanta, GA: Centers for Disease Control and Prevention; 2022."},{"key":"1067_CR34","doi-asserted-by":"crossref","unstructured":"Isturiz RE, Ramirez J, Self WH, et al. Pneumococcal epidemiology among US adults hospitalized for community-acquired pneumonia. Vaccine. 2019;37(25):3352\u201361.","DOI":"10.1016\/j.vaccine.2019.04.087"},{"key":"1067_CR35","doi-asserted-by":"publisher","unstructured":"Self WH, Johnson KD, Resser JJ, et al. Prevalence, clinical severity, and serotype distribution of pneumococcal pneumonia among adults hospitalized with community-acquired pneumonia in Tennessee and Georgia, 2018\u20132022. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae316.","DOI":"10.1093\/cid\/ciae316"},{"key":"1067_CR36","unstructured":"Centers for Disease Control and Prevention. CDC vaccine price list. 2024. Available from: https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html. Accessed 20 July 2024."},{"key":"1067_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.04.002","author":"SM Altawalbeh","year":"2024","unstructured":"Altawalbeh SM, Wateska AR, Nowalk MP, et al. Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older. Vaccine. 2024. https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.002.","journal-title":"Vaccine"},{"key":"1067_CR38","unstructured":"Micromedex Solutions. Capvaxive. Red Book online. 2024. https:\/\/www.micromedexsolutions.com\/home\/dispatch"},{"issue":"1","key":"1067_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.amepre.2006.03.008","volume":"31","author":"MV Maciosek","year":"2006","unstructured":"Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006;31(1):72\u20139. https:\/\/doi.org\/10.1016\/j.amepre.2006.03.008.","journal-title":"Am J Prev Med"},{"key":"1067_CR40","unstructured":"Stoecker C. Economic assessment of PCV15 & PCV20. Presentation to the ACIP, June 25, 2021. Atlanta, GA: Centers for Disease Control and Prevention; 2021."},{"issue":"4","key":"1067_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","volume":"36","author":"JM McLaughlin","year":"2015","unstructured":"McLaughlin JM, McGinnis JJ, Tan L, Mercatante A, Fortuna J. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev. 2015;36(4):259\u201373.","journal-title":"J Prim Prev"},{"issue":"48","key":"1067_CR42","doi-asserted-by":"publisher","first-page":"7634","DOI":"10.1016\/j.vaccine.2010.09.049","volume":"28","author":"JL Rubin","year":"2010","unstructured":"Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634\u201343.","journal-title":"Vaccine"},{"issue":"6","key":"1067_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/13696998.2018.1542520","volume":"22","author":"SD Grosse","year":"2019","unstructured":"Grosse SD, Krueger KV, Pike J. Estimated annual and lifetime labor productivity in the United States, 2016: implications fro economic evaluations. J Med Econ. 2019;22(6):501\u20138.","journal-title":"J Med Econ"},{"issue":"5","key":"1067_CR44","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","volume":"46","author":"M-JJ Mangen","year":"2015","unstructured":"Mangen M-JJ, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407\u201316.","journal-title":"Eur Respir J"},{"issue":"12","key":"1067_CR45","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","volume":"372","author":"MJ Bonten","year":"2015","unstructured":"Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114\u201325.","journal-title":"N Engl J Med"},{"issue":"50","key":"1067_CR46","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1016\/j.vaccine.2013.10.024","volume":"31","author":"BH Cho","year":"2013","unstructured":"Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011\u201321.","journal-title":"Vaccine"},{"issue":"48","key":"1067_CR47","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","volume":"30","author":"NJ Andrews","year":"2012","unstructured":"Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802\u20138.","journal-title":"Vaccine"},{"issue":"49","key":"1067_CR48","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.1016\/j.vaccine.2013.09.049","volume":"31","author":"W Rudnick","year":"2013","unstructured":"Rudnick W, Liu Z, Shigayeva A, et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995\u20132011. Vaccine. 2013;31(49):5863\u201371.","journal-title":"Vaccine"},{"key":"1067_CR49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","volume":"6","author":"A Djennad","year":"2018","unstructured":"Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42\u201350.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"1067_CR50","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.vaccine.2018.01.049","volume":"36","author":"JA Suaya","year":"2018","unstructured":"Suaya JA, Jiang Q, Scott DA, et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 2018;36(11):1477\u201383.","journal-title":"Vaccine"},{"issue":"10","key":"1067_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003326","volume":"17","author":"H Lawrence","year":"2020","unstructured":"Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLoS Med. 2020;17(10): e1003326.","journal-title":"PLoS Med"},{"key":"1067_CR52","unstructured":"Stoecker C. Economic assessment of PCV21 in U.S. adults. Atlanta, GA: Centers for Disease Control and Prevention; 2024."},{"issue":"2","key":"1067_CR53","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1542\/peds.2012-3350","volume":"132","author":"C Stoecker","year":"2013","unstructured":"Stoecker C, Hampton LM, Link-Gelles R, et al. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013;132(2):e324\u201332.","journal-title":"Pediatrics"},{"key":"1067_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00805-5","author":"M Treskova","year":"2019","unstructured":"Treskova M, Scholz SM, Kuhlmann A. Cost effectiveness of elderly pneumococcal vaccination in presence of higher-valent pneumococcal conjugate childhood vaccination: systematic literature review with focus on methods and assumptions. PharmacoEconomics. 2019. https:\/\/doi.org\/10.1007\/s40273-019-00805-5.","journal-title":"PharmacoEconomics."},{"key":"1067_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149540","volume":"11","author":"AJ van Hoek","year":"2016","unstructured":"van Hoek AJ, Miller E. Cost-effectiveness of vaccinating immunocompetent 65 year olds with the 13-valent pneumococcal conjugate vaccine in England. PLoS One 2016;11:e0149540. https:\/\/doi.org\/10.1371\/journal.pone.0149540.","journal-title":"PLoS One"},{"issue":"7","key":"1067_CR56","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40273-017-0508-2","volume":"35","author":"EJ Dasbach","year":"2017","unstructured":"Dasbach EJ, Elbasha EH. Verification of decision-analytic models for health economic evaluations: an overview. Pharmacoeconomics. 2017;35(7):673\u201383.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1067_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12916-024-03277-3","volume":"22","author":"PT de Boer","year":"2024","unstructured":"de Boer PT, van Werkhoven CH, van Hoek AJ, et al. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands. BMC Med. 2024;22(1):69.","journal-title":"BMC Med"},{"issue":"30","key":"1067_CR58","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1016\/j.vaccine.2023.06.007","volume":"41","author":"AR Wateska","year":"2023","unstructured":"Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults. Vaccine. 2023;41(30):4431\u20137.","journal-title":"Vaccine"},{"key":"1067_CR59","unstructured":"Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822\u20135."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01067-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T15:10:09Z","timestamp":1732201809000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01067-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01067-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Zinan Yi, Kwame Owusu-Edusei, and Elamin Elbasha are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may hold stock or stock options in Merck & Co., Inc., Rahway, NJ, USA. V116 was developed by Merck & Co., Inc., Rahway, NJ, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in\u2014or a financial conflict with\u2014the subject matter or materials discussed in this manuscript apart from those disclosed herewith.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}